Hepatocellular InjuryHOPE-ECD-DBDNCT03124641
HOPE for Human Extended Criteria and Donation After Brain Death Donor (ECD-DBD) Liver Allografts
A study testing Hypothermic oxygenated perfusion (HOPE) and Conventional cold storage (CCS) in people with Hepatocellular Injury and Liver Transplant, run by University Hospital, Aachen at 4 sites in 2 countries.
Trial summary
The purpose of this study is to test the effects of hypothermic oxygenated machine perfusion (HOPE) in a phase-II prospective multicenter randomized clinical trial (RCT) on extended criteria donor allografts (ECD) in donation after brain death (DBD) orthotropic liver-transplantation (OLT) (HOPE-ECD-DBD). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hepatocellular Injury, Liver Transplant
- What is being tested?
- Hypothermic oxygenated perfusion (HOPE) and Conventional cold storage (CCS)
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 4 sitesin 2 countries
- Study dates
- 17 Jan 2017to 30 Sep 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- -Patients with signed informed consent, suffering from end stage-liver disease and/or malignant liver tumors listed for liver transplantation and receiving ECD organs.
- ECD Criteria are defined as:
- Donors 65 years of age and older
- Intensive therapy of the donor was required before donation for at least 7 days, --Obesity of the donor with a Body Mass Index > 30
- Fatty liver (with histology) > 40 %
- Serum-Sodium > 165 mmol/l
- Serum AST or ALT > 3 x normal, Serum-Bilirubin > 2 mg/dl)
Who cannot join
- Recipients of split of living donor liver transplants
- Previous liver transplantation
- Combined transplantations (liver-kidney, liver-lung, etc.)
- Participation in other liver related trials
- The subject received an investigational drug within 30 days prior to inclusion
- The subject is unwilling or unable to follow the procedures outlined in the protocol
Show all 9Show fewer
- The subject is mentally or legally incapacitated
- Patient is not able to understand the procedures due to language barriers
- Family members of the investigators or employees of the participating department
Trial locations and contacts
4 sites in 2 countries.
4 sites in 2 countries
Germany3 sites
Department of Surgery and Transplantation, University Hospital RWTH Aachen
Aachen, 52074
Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Germany
Berlin, 13353
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich
Munich, 81377
Czechia1 site
Department of Transplantation Surgery, Institute for Clinical and Experimental Medicine
Prague
About this study
Official title: Hypothermic Oxygenated Machine Perfusion (HOPE) for Liver Transplantation of Human Liver Allografts From Extended Criteria Donors (ECD) in Donation After Brain Death (DBD); a Multicenter Randomized Controlled Trial (HOPE ECD-DBD)
The purpose of this study is to test the effects of hypothermic oxygenated machine perfusion (HOPE) in a phase-II prospective multicenter randomized clinical trial (RCT) on extended criteria donor allografts (ECD) in donation after brain death (DBD) orthotropic liver-transplantation (OLT) (HOPE-ECD-DBD). Human whole organ liver grafts will be submitted to 1-2 hours of HOPE via the portal vein directly before implantation and going to be compared to a control-group of patients transplanted after conventional cold storage (CCS). Primary (early graft injury) and secondary (e.g. postoperative complications, hospital stay, survival) objectives are going to be analysed in a 12 month follow up. Ischemia-reperfusion (I/R) injury and inflammation will be assessed using liver tissue, serum and bile samples as well as machine perfusion perfusate.
To improve the availability of donor allografts and reduce waiting list mortality, graft acceptance criteria were extended increasingly over the decades. The use of extended criteria donor (ECD) allografts is associated with higher incidences of primary graft non-function (PNF) and/or delayed graft function (DGF). As such, several strategies have been developed aiming at "reconditioning" poor quality ECD grafts. HOPE has been tested intensively in pre-clinical animal experiments. Although, its known that HOPE can exert its reconditioning effect via cellular and mitochondrial pathways in the endothelial and parenchymal cells, there is still scarce evidence available on the exact subcellular mechanism of HOPE induced organ protection in the clinical scenario of liver transplantation. In donation after cardiac death (DCD) OLT, the positive effects of HOPE have been shown to reduce the incidence of biliary complications, mitochondrial damage and improve the overall cellular energy-status.
In the HOPE setting, organ perfusion is performed in the transplant center shortly before the actual implantation with oxygenated perfusate using an extra corporal organ perfusion system. The first clinical study with this promising technique was recently reported in a Swiss cohort of patients who received DCD allografts. In organ donation after brain death (DBD), the only legally accepted approach for organ donation in most countries, HOPE and its effect on early graft injury and postoperative complications remains to be elucidated.
Read the detailed description
The present RCT comprises two groups, a perfusion (group 1; HOPE) and a control conventional cold storage (group 2; CCS) group. Patients with proven written informed consent on waiting list for orthotopic liver transplantation will be recruited. Randomization is performed with an online randomizing tool for clinical trials (www.randomizer.at) at the time of allograft arrival at the transplant center and acceptance of the organ for transplantation. Stratified randomization model will be used to ensure balance of prognostic variables between the treatment groups.
In case of randomisation to group 1, HOPE will be applied to the allograft in the operation room, directly after the back table preparation. The application of HOPE to the liver allograft will not delay the implantation due to the fact that it is performed parallel to the recipient hepatectomy.
Commercially available and machine-perfusion approved Belzer MPS® UW solution (Belzer Organ Preservation Solutions, Bridge for Life) will be used as perfusate for machine perfusion.
Patients will be followed for one year after OLT.
Interim analysis: After n=12 per randomized group is reached, data will be analyzed by an independent Data Monitoring Committee. The RCT will be stopped if one of the following criteria is reached:
Significantly higher serum ALT levels (p<0.001 using Student's t-test) in the HOPE group compared to the CCS group (Efficacy).
The proportion of Grade ≥ III complications is significantly higher (p<0.05, Fischer's exact test) in the HOPE group when compared to the CCS group (Safety).
- Conditions
- Hepatocellular Injury, Liver Transplant
- Being tested
- Hypothermic oxygenated perfusion (HOPE), Conventional cold storage (CCS)
- Keywords
- Hypothermic oxygenated machine perfusion, Orthotopic liver transplantation, Extended criteria donation, Donation after brain death, HOPE
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hypothermic oxygenated perfusion (HOPE)Device
Also called Hypothermic machine perfusion (HMP)
HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
Conventional cold storage (CCS)Procedure or surgery
Also called CCS
Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
| Study group | Role | What they receive |
|---|---|---|
| Hypothermic oxygenated perfusion (HOPE) | Experimental | Application of Hypothermic machine perfusion (HOPE) for 1-2 hours Receives: Device: Hypothermic oxygenated perfusion (HOPE) |
| Conventional cold storage (CCS) | Active comparator | Conventional cold storage Receives: Procedure: Conventional cold storage (CCS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Early graft injury
Peak serum alanine aminotransferase-ALT
Measured: During the first week postoperatively (absolute and relative delta)
Secondary outcomes (8)
Postoperative complications
Clavien-Dindo complication score
Measured: Subjects will be followed for one year postoperatively
Cumulative postoperative complications
Comprehensive complication index (CCI)
Measured: Subjects will be followed for one year postoperatively
Early allograft dysfunction (EAD)
Olthoff criteria (bilirubin 10mg/dL on day 7, international normalized ratio 1.6 on day 7, and alanine or aspartate aminotransferases >2000 IU/L)
Measured: During the first week postoperatively
Duration of intensive care stay
Duration of ICU stay
Measured: Subjects will be followed for one year postoperatively
Duration of hospital stay
Duration of hospitalisation
Measured: Subjects will be followed for one year postoperatively
One-year recipient- and graft survival
One year patient and graft survival
Measured: Subjects will be followed for one year postoperatively
Ischemia-reperfusion injury and inflammatory responses
Liver samples taken upon arrival of the organ (before HOPE or corresponding cold-storage), and at the end of the implantation procedure before closure of the abdomen
Measured: Before preservation (HOPE or CCS), after liver implantation (0-3 hrs)
(in selected centers) Biliary epithelial cell injury
Bile samples collected from T-Drain
Measured: Postoperative days 1, 2, and 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2017
- Study start17 Jan 2017
- Primary completion30 Sep 2020
- Study completion30 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Hepatocellular InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Aachen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Georg Lurje, M.D., University Hospital, Aachen
- Investigators
- Georg Lurje, M.D., Principal investigator, RWTH Aachen University I Charité-Universitätsmedizin Berlin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03124641
- Sponsor's protocol ID
- EK 049/17
- Acronym
- HOPE-ECD-DBD
- Status last verified
- Jan 2021
- First submitted
- 20 Mar 2017
- Last updated
- 28 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Czigany Z, Schoning W, Ulmer TF, Bednarsch J, Amygdalos I, Cramer T, Rogiers X, Popescu I, Botea F, Fronek J, Kroy D, Koch A, Tacke F, Trautwein C, Tolba RH, Hein M, Koek GH, Dejong CHC, Neumann UP, Lurje G. Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD). BMJ Open. 2017 Oct 10;7(10):e017558. doi: 10.1136/bmjopen-2017-017558.
PubMed 29018070Schliephake F, Lurje I, Uluk D, Eden J, Czigany Z, Pein J, Husen P, Engelmann C, Michalski C, Kohlhepp M, Strnad P, Dutkowski P, Tacke F, Neumann UP, Meierhofer D, Lurje G. Effects of hypothermic oxygenated machine perfusion on bile composition after liver transplantation - Findings from a randomized controlled trial. JHEP Rep. 2025 Oct 17;8(2):101647. doi: 10.1016/j.jhepr.2025.101647. eCollection 2026 Feb.
PubMed 41551407Czigany Z, Pratschke J, Fronek J, Guba M, Schoning W, Raptis DA, Andrassy J, Kramer M, Strnad P, Tolba RH, Liu W, Keller T, Miller H, Pavicevic S, Uluk D, Kocik M, Lurje I, Trautwein C, Mehrabi A, Popescu I, Vondran FWR, Ju C, Tacke F, Neumann UP, Lurje G. Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death: Results From a Multicenter Randomized Controlled Trial (HOPE ECD-DBD). Ann Surg. 2021 Nov 1;274(5):705-712. doi: 10.1097/SLA.0000000000005110.
PubMed 34334635
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hypothermic Oxygenated Machine Perfusion (HOPE) for Liver Transplantation of Human Liver Allografts From Extended Criteria Donors (ECD) in Donation After Brain Death (DBD); a Multicenter Randomized Controlled Trial (HOPE ECD-DBD)
- ClinicalTrials.gov ID
- NCT03124641
- Acronym / sponsor ID
- HOPE-ECD-DBD / EK 049/17
- Conditions
- Hepatocellular Injury, Liver Transplant
- Keywords
- Hypothermic oxygenated machine perfusion, Orthotopic liver transplantation, Extended criteria donation, Donation after brain death, HOPE
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- University Hospital, AachenUniversity, hospital or other
- Study start
- 17 Jan 2017 (actual)
- Primary completion
- 30 Sep 2020 (actual)
- Study completion
- 30 Sep 2020 (actual)
- First posted
- 24 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test the effects of hypothermic oxygenated machine perfusion (HOPE) in a phase-II prospective multicenter randomized clinical trial (RCT) on extended criteria donor allografts (ECD) in donation after brain death (DBD) orthotropic liver-transplantation (OLT) (HOPE-ECD-DBD). Human whole organ liver grafts will be submitted to 1-2 hours of HOPE via the portal vein directly before implantation and going to be compared to a control-group of patients transplanted after conventional cold storage (CCS). Primary (early graft injury) and secondary (e.g. postoperative complications, hospital stay, survival) objectives are going to be analysed in a 12 month follow up. Ischemia-reperfusion (I/R) injury and inflammation will be assessed using liver tissue, serum and bile samples as well as machine perfusion perfusate.
To improve the availability of donor allografts and reduce waiting list mortality, graft acceptance criteria were extended increasingly over the decades. The use of extended criteria donor (ECD) allografts is associated with higher incidences of primary graft non-function (PNF) and/or delayed graft function (DGF). As such, several strategies have been developed aiming at "reconditioning" poor quality ECD grafts. HOPE has been tested intensively in pre-clinical animal experiments. Although, its known that HOPE can exert its reconditioning effect via cellular and mitochondrial pathways in the endothelial and parenchymal cells, there is still scarce evidence available on the exact subcellular mechanism of HOPE induced organ protection in the clinical scenario of liver transplantation. In donation after cardiac death (DCD) OLT, the positive effects of HOPE have been shown to reduce the incidence of biliary complications, mitochondrial damage and improve the overall cellular energy-status.
In the HOPE setting, organ perfusion is performed in the transplant center shortly before the actual implantation with oxygenated perfusate using an extra corporal organ perfusion system. The first clinical study with this promising technique was recently reported in a Swiss cohort of patients who received DCD allografts. In organ donation after brain death (DBD), the only legally accepted approach for organ donation in most countries, HOPE and its effect on early graft injury and postoperative complications remains to be elucidated.
Detailed description
The present RCT comprises two groups, a perfusion (group 1; HOPE) and a control conventional cold storage (group 2; CCS) group. Patients with proven written informed consent on waiting list for orthotopic liver transplantation will be recruited. Randomization is performed with an online randomizing tool for clinical trials (www.randomizer.at) at the time of allograft arrival at the transplant center and acceptance of the organ for transplantation. Stratified randomization model will be used to ensure balance of prognostic variables between the treatment groups.
In case of randomisation to group 1, HOPE will be applied to the allograft in the operation room, directly after the back table preparation. The application of HOPE to the liver allograft will not delay the implantation due to the fact that it is performed parallel to the recipient hepatectomy.
Commercially available and machine-perfusion approved Belzer MPS® UW solution (Belzer Organ Preservation Solutions, Bridge for Life) will be used as perfusate for machine perfusion.
Patients will be followed for one year after OLT.
Interim analysis: After n=12 per randomized group is reached, data will be analyzed by an independent Data Monitoring Committee. The RCT will be stopped if one of the following criteria is reached:
Significantly higher serum ALT levels (p<0.001 using Student's t-test) in the HOPE group compared to the CCS group (Efficacy).
The proportion of Grade ≥ III complications is significantly higher (p<0.05, Fischer's exact test) in the HOPE group when compared to the CCS group (Safety).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Hypothermic oxygenated perfusion (HOPE) | Experimental | Device: Hypothermic oxygenated perfusion (HOPE)Application of Hypothermic machine perfusion (HOPE) for 1-2 hours |
| Conventional cold storage (CCS) | Active comparator | Procedure: Conventional cold storage (CCS)Conventional cold storage |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- -Patients with signed informed consent, suffering from end stage-liver disease and/or malignant liver tumors listed for liver transplantation and receiving ECD organs.
- Donors 65 years of age and older
- Intensive therapy of the donor was required before donation for at least 7 days, --Obesity of the donor with a Body Mass Index > 30
- Fatty liver (with histology) > 40 %
- Serum-Sodium > 165 mmol/l
Key exclusion criteria (9 listed)
- Recipients of split of living donor liver transplants
- Previous liver transplantation
- Combined transplantations (liver-kidney, liver-lung, etc.)
- Participation in other liver related trials
- The subject received an investigational drug within 30 days prior to inclusion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hypothermic oxygenated perfusion (HOPE)Also: Hypothermic machine perfusion (HMP)HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa | Device | Hypothermic oxygenated perfusion (HOPE) |
| Conventional cold storage (CCS)Also: CCSConventional static cold storage (CCS) on temperature 4-6 °C from organ procurement | Procedure or surgery | Conventional cold storage (CCS) |
Primary outcome
Early graft injury
Time frame: During the first week postoperatively (absolute and relative delta)
Peak serum alanine aminotransferase-ALT
8 secondary outcomes
Postoperative complications
Time frame: Subjects will be followed for one year postoperatively
Cumulative postoperative complications
Time frame: Subjects will be followed for one year postoperatively
Early allograft dysfunction (EAD)
Time frame: During the first week postoperatively
Duration of intensive care stay
Time frame: Subjects will be followed for one year postoperatively
Duration of hospital stay
Time frame: Subjects will be followed for one year postoperatively
One-year recipient- and graft survival
Time frame: Subjects will be followed for one year postoperatively
Ischemia-reperfusion injury and inflammatory responses
Time frame: Before preservation (HOPE or CCS), after liver implantation (0-3 hrs)
(in selected centers) Biliary epithelial cell injury
Time frame: Postoperative days 1, 2, and 3
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2021.
- Background: PubMed 29018070Czigany Z, Schoning W, Ulmer TF, Bednarsch J, Amygdalos I, Cramer T, Rogiers X, Popescu I, Botea F, Fronek J, Kroy D, Koch A, Tacke F, Trautwein C, Tolba RH, Hein M, Koek GH, Dejong CHC, Neumann UP, Lurje G. Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD). BMJ Open. 2017 Oct 10;7(10):e017558. doi: 10.1136/bmjopen-2017-017558.
- Derived from this study: PubMed 41551407Schliephake F, Lurje I, Uluk D, Eden J, Czigany Z, Pein J, Husen P, Engelmann C, Michalski C, Kohlhepp M, Strnad P, Dutkowski P, Tacke F, Neumann UP, Meierhofer D, Lurje G. Effects of hypothermic oxygenated machine perfusion on bile composition after liver transplantation - Findings from a randomized controlled trial. JHEP Rep. 2025 Oct 17;8(2):101647. doi: 10.1016/j.jhepr.2025.101647. eCollection 2026 Feb.
- Derived from this study: PubMed 34334635Czigany Z, Pratschke J, Fronek J, Guba M, Schoning W, Raptis DA, Andrassy J, Kramer M, Strnad P, Tolba RH, Liu W, Keller T, Miller H, Pavicevic S, Uluk D, Kocik M, Lurje I, Trautwein C, Mehrabi A, Popescu I, Vondran FWR, Ju C, Tacke F, Neumann UP, Lurje G. Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death: Results From a Multicenter Randomized Controlled Trial (HOPE ECD-DBD). Ann Surg. 2021 Nov 1;274(5):705-712. doi: 10.1097/SLA.0000000000005110.
- HOPE ECD-DBD webpageLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Injury
Recruiting
Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis
Hepatic Cytolysis
RecruitingPhase 4
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage
Hemorrhagic Disorders
RecruitingObservational study
Digital Early Warning System for Acute Lung Injury in Liver Surgery
Acute Lung Injury(ALI), Liver Cirrhosis
Not yet recruiting
Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer
Liver Cancer, Adult
RecruitingPhase 1
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Hepatic Insufficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Georg Lurje, M.D. principal investigator
RWTH Aachen University I Charité-Universitätsmedizin Berlin
4 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hypothermic oxygenated perfusion (HOPE) and Conventional cold storage (CCS) in people with Hepatocellular Injury and Liver Transplant, run by University Hospital, Aachen at 4 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Germany, Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Early graft injury (time frame: During the first week postoperatively (absolute and relative delta)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03124641, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2021.